Education
About Us
Working with TipRanks
Follow Us
BICO Group AB Class B (SE:BICO)
:BICO
Top Page
BICO Group AB Class B
(OTC:BICO)
50Neutral
BICO Group AB Class B (BICO) vs. S&P 500 (SPY)
Market Cap
$2.50B
Dividend YieldN/A
Average Volume (3M)197.29K
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth-12.58%
EPS Growth88.84%
CountrySE
Employees695
SectorHealthcare
Sector Strength48
IndustryMedical - Devices
Share Statistics
EPS (TTM)-3.28
Shares Outstanding69,074,900
10 Day Avg. Volume165,685
30 Day Avg. Volume197,293
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.00
P/FCF Ratio12.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BICO Group AB Class B Business Overview & Revenue Model
Company DescriptionBICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
How the Company Makes MoneyBICO Group AB generates revenue primarily through the sale of its bioprinting, biosciences, and bioautomation products and services. These offerings are marketed to academic institutions, pharmaceutical companies, and clinical research organizations that require advanced tools for research and development purposes. The company also benefits from strategic partnerships and collaborations with key industry players, which help expand its market reach and drive sales. Additionally, BICO may generate income from licensing agreements and providing specialized consulting services to its clients, further contributing to its revenue streams.
BICO Group AB Class B Financial Statement Overview
Summary
BICO Group AB shows robust revenue growth and improved operational efficiency, reflected in the positive EBITDA margin. However, profitability remains a concern with a negative net profit margin, and the company must address its stockholders' equity decline. Strong cash flow management is a positive aspect, indicating potential financial health improvement.Income Statement
The company shows strong revenue growth over the years, but profitability is a concern. The TTM (Trailing-Twelve-Months) data indicates a negative net profit margin and EBIT margin, reflecting ongoing operational challenges. However, the EBITDA margin is positive, suggesting some operational efficiency. The increase in gross profit margin indicates improved cost management.60
Neutral
Balance Sheet
The balance sheet reveals a moderate debt-to-equity ratio and a reasonable equity ratio, indicating a stable financial structure. However, the decrease in stockholders' equity over time could be a concern if it continues. The company needs to improve its return on equity, which is currently negative due to ongoing losses.50
Neutral
Cash Flow
The cash flow statement shows a positive trend with improving free cash flow and operating cash flow. The free cash flow to net income ratio and operating cash flow to net income ratio are positive, indicating effective cash management despite negative net income. The company has reduced its financing cash flow significantly, which might impact future liquidity.65
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2022 | Dec 2021 | Sep 2020 | Sep 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.99B | 1.95B | 2.24B | 1.26B | 176.79M | 105.46M | Gross Profit |
| 1.08B | 1.01B | 1.83B | 1.00B | 163.62M | 91.36M | EBIT |
| -181.70M | -289.10M | -618.30M | -160.00M | -66.09M | -3.75M | EBITDA |
| 296.10M | 437.60M | 322.30M | 31.80M | -39.50M | 5.82M | Net Income Common Stockholders |
| -211.30M | -5.50M | -835.70M | -229.20M | -61.89M | 581.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 596.50M | 598.00M | 925.20M | 1.48B | 995.80M | 109.12M | Total Assets |
| 4.74B | 5.48B | 10.20B | 9.75B | 1.65B | 603.12M | Total Debt |
| 1.41B | 1.76B | 1.85B | 1.61B | 62.49M | 600.00K | Net Debt |
| 811.60M | 1.17B | 927.90M | 1.13B | -746.20M | -39.24M | Total Liabilities |
| 2.08B | 2.48B | 3.26B | 2.95B | 126.74M | 53.48M | Stockholders Equity |
| 2.64B | 2.98B | 6.91B | 6.77B | 1.52B | 549.64M |
| Cash Flow | Free Cash Flow | ||||
| 193.30M | 72.70M | -799.00M | -676.20M | -154.12M | -51.56M | Operating Cash Flow |
| 252.30M | 158.40M | -269.40M | -409.20M | -71.82M | -15.82M | Investing Cash Flow |
| 165.80M | 128.00M | 212.90M | -4.45B | -200.90M | -110.20M | Financing Cash Flow |
| -484.20M | -200.70M | 455.30M | 4.90B | 1.04B | 140.33M |
BICO Group AB Class B Technical Analysis
Neutral
35.12
Price Trends
36.23
Negative
34.92
Positive
37.51
Negative
Market Momentum
-0.28
Positive
48.90
Neutral
31.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BICO, the sentiment is Neutral. The current price of 35.12 is below the 20-day moving average (MA) of 36.09, below the 50-day MA of 36.23, and below the 200-day MA of 37.51, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 48.90 is Neutral, neither overbought nor oversold. The STOCH value of 31.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BICO.
BICO Group AB Class B Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
SE:BICO
BICO Group AB Class B
35.12
-10.88
-23.65%
CLVSF
CellaVision AB
16.82
-4.00
-19.21%
PXMBF
Paxman AB
3.50
0.70
25.00%
XVIPF
Xvivo Perfusion AB
33.52
-2.55
-7.07%
DE:47H
Humana AB
3.33
0.76
29.57%
DE:6XP
Xspray Pharma AB
3.08
-1.21
-28.21%
BICO Group AB Class B Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q1-2025)
| % Change Since: -10.91%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Neutral
The earnings call presents a mixed picture. While there are strategic divestments and specific areas of growth, such as Bioprinting and Life Science Solutions, the company faces significant challenges with negative organic growth, especially in Lab Automation, and broader macroeconomic uncertainties impacting its performance.Q1-2025 Updates
Positive Updates
Divestment of MatTek and Visikol
BICO has entered into an agreement to divest MatTek and Visikol to Sartorius for $80 million, which will help move the company into a net cash position during Q2 2025.
Positive Developments in Life Science Solutions and Bioprinting
Despite a decline in overall sales, both Life Science Solutions and Bioprinting showed growth due to operational excellence, with Bioprinting achieving an organic growth of 41%.
Cash Flow from Operating Activities
The cash flow from operating activities was SEK 77 million, which was explained by the cash collection from quarter four sales in 2024.
Improved Gross Margin
Gross margin improved to 54% due to product mix and operational excellence initiatives.
Negative Updates
Negative Organic Growth
Sales amounted to SEK 389 million, corresponding to a negative organic growth of 19%.
Challenges in Lab Automation
Lab Automation faced negative organic growth of 58% due to fewer project starts and closures, and seasonal effects.
Macroeconomic Uncertainty Impact
Continued uncertain macroeconomic dynamics, including changes to U.S. policy focus and reduced NIH funding, resulted in slower academic purchases and challenges.
Adjusted EBITDA Decline
Adjusted EBITDA was negative SEK 12 million, corresponding to a margin of negative 3%, although it was in line with Q1 2024.
Company Guidance
During BICO's Q1 2025 earnings call, CEO Maria Forss and CFO Jacob Thordenberg provided detailed guidance on the company's financial performance and strategic initiatives. The quarter's sales amounted to SEK 389 million, reflecting a negative organic growth of 19%, while adjusted EBITDA remained stable at negative SEK 12 million, with a margin of negative 3%. The company reported a cash flow from operating activities of SEK 77 million and a significant reduction in net working capital to 12% of last 12-month sales. BICO also highlighted plans to transition into a net cash position in Q2 2025 following the divestment of MatTek and Visikol, expected to generate $80 million. This strategy aligns with their focus on lab automation and selected workflows, as well as efforts to mitigate macroeconomic uncertainties, including potential tariffs. The company has strategically moved manufacturing out of China and adjusted logistics to enhance cost efficiency. BICO's business areas showed varied performance, with Life Science Solutions and Bioprinting experiencing growth, while Lab Automation faced challenges due to fewer project starts and a strong comparison quarter in 2024.BICO Group AB Class B Corporate Events
BICO Group AB Announces Key Resolutions at Annual General Meeting
May 8, 2025
At the Annual General Meeting, BICO Group AB resolved several key issues, including the adoption of the 2024 financial statements and the decision not to distribute dividends, opting instead to carry forward profits. The meeting also saw the re-election and election of board members, the approval of remuneration guidelines, and the implementation of new incentive programs designed to align key personnel interests with those of shareholders, potentially impacting the company’s ability to attract and retain talent.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.